CING · Cingulate Inc
United States · RS rating 43 · As of 2026-10-14
| Price | 4.57 USD |
|---|---|
| 1-day change | -3.2% |
| RS rating (overall / 1M / 3M / 12M) | 43 / 22 / 76 / 64 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 24 / 33 / 36 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +29.6% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +60.8% |
| Market cap (USD) | $68.8M |